Abstract:AIM: To explore Chinese physicians' perceptions towards fecal microbiota transplantation (FMT) and to provide information and an assessment of FMT development in China.METHODS: A self-administered questionnaire was developed according to the FMT practice guidelines and was distributed to physicians in hospitals via Internet Research Electronic Data Capture (REDcap) software and electronic mails to assess their attitudes toward and knowledge of FMT. The questionnaire included a brief introduction of FMT that was followed by 20 questions. The participants were required to respond voluntarily, under the condition of anonymity and without compensation. Except for the fill-in-the-blank questions, all of the other questions were required in the REDcap data collection systems, and the emailed questionnaires were completed based on eligibility.RESULTS: Up to December 9, 2014, 844 eligible questionnaires were received out of the 980 distributed questionnaires, with a response rate of 86.1%. Among the participants, 87.3% were from tertiary hospitals, and there were 647 (76.7%) gastroenterologists and 197 (23.3%) physicians in other departments (non-gastroenterologists). Gastroenterologists' awareness of FMT prior to the survey was much higher than non-gastroenterologists' (54.3 vs 16.5%, P < 0.001); however, acceptance of FMT was not statistically different (92.4 vs 87.1%, P = 0.1603). Major concerns of FMT included the following: acceptability to patients (79.2%), absence of guidelines (56.9%), and administration and ethics (46.5%). On the basis of understanding, the FMT indications preferred by physicians were recurrent Clostridium difficile infection (86.7%), inflammatory bowel disease combined with Clostridium difficile infection (78.6%), refractory ulcerative colitis (70.9%), ulcerative colitis (65.4%), Crohn's disease (59.4%), chronic constipation (43.7%), irritable bowel syndrome (39.1%), obesity (28.1%) and type 2 diabetes (23.9%). For donor selection, the majority of physicians preferred individuals with a similar gut flora environment to the recipients. 76.6% of physicians chose lower gastrointestinal tract as the administration approach. 69.2% of physicians considered FMT a safe treatment.CONCLUSION: Chinese physicians have awareness and a high acceptance of FMT, especially gastroenterologists, which provides the grounds and conditions for the development of this novel treatment in China. Physicians' greatest concerns were patient acceptability and absence of guidelines.

Editorial: Multi-Omics Study on Gut Microbiota Related to Faecal Microbiota Transplantation

Microbiota Transplantation: Concept, Methodology and Strategy for Its Modernization

Fecal microbiota transplantation in clinical practice: Present controversies and future prospects

Editorial: Microbiome in IBD: from Composition to Therapy.

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

A comprehensive approach to stool donor screening for faecal microbiota transplantation in China

An update on clinical practice of fecal microbiota transplantation

The Rigorous Screening and Ethics of Donor for Faecal Microbiota Transplantation in China

Preclinical Safety, Effectiveness Evaluation, and Screening of Functional Bacteria for Fecal Microbiota Transplantation Based on Germ-Free Animals

Gut Microbiota Community Adaption During Young Children Fecal Microbiota Transplantation by 16s Rdna Sequencing

Gut microbial genomes with paired isolates from China illustrate probiotic and cardiometabolic effects

Donor-recipient Intermicrobial Interactions Impact Transfer of Subspecies and Fecal Microbiota Transplantation Outcome.

Fecal Microbiota Transplantation Donor and Dietary Fiber Intervention Collectively Contribute to Gut Health in a Mouse Model

Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice

Fecal microbiota transplantation for the treatment of intestinal and extra‐intestinal diseases: Mechanism basis, clinical application, and potential prospect

An Ecological Framework to Understand the Efficacy of Fecal Microbiota Transplantation

Fecal microbiota transplantation attenuates Escherichia coli infected outgrowth by modulating the intestinal microbiome

Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021

Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients.

Chinese Physicians’ Perceptions of Fecal Microbiota Transplantation

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook